Elicio Therapeutics, Inc. - ELTX STOCK NEWS

Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology firm, has announced the commencement of an underwritten public offering of its common stock and accompanying warrants. This offering includes pre-funded warrants for certain investors as an alternative to common stock.

The size and terms of the offering are yet to be determined and are subject to market conditions. The proceeds will be utilized for advancing Elicio's development pipeline, as well as for working capital and general corporate purposes. JonesTrading Institutional Services is the sole book-running manager for this offering.

A shelf registration statement for these securities was filed and became effective on June 11, 2024, with the SEC. Preliminary prospectus supplements and accompanying documents will be available on the SEC's website.

Elicio Therapeutics reported preliminary data from its AMPLIFY-7P Phase 1a study of ELI-002 7P, an investigational therapeutic cancer vaccine. Administered as a monotherapy at the Phase 2 dose of 4.9mg AMP-peptide, ELI-002 7P shows promising disease-free survival (DFS) data in pancreatic ductal adenocarcinoma patients.

As of May 24, 2024, the study includes 14 patients with minimal residual disease and a median follow-up of 29.1 weeks. The median DFS has not been reached for patients receiving the 4.9mg dose, compared to 12.6 weeks for those on the 1.4mg dose. Patients showing tumor biomarker reduction and strong T cell response had no progression events, whereas those without biomarker response had a median DFS of 11.0 weeks.

Elicio plans further updates on the AMPLIFY Phase 1 trials later in 2024, with a Phase 2 interim analysis expected in Q1 2025.

Elicio Therapeutics (Nasdaq: ELTX), a biotechnology company specializing in immunotherapies for cancer, announced on June 18, 2024, the issuance of 5,400 inducement stock options to two new employees. These options, granted on June 17, 2024, align with Nasdaq Listing Rule 5635(c)(4) and were approved by the board's Compensation Committee under the 2024 Inducement Incentive Award Plan. The options are priced at $7.98 each, reflecting the closing price on the grant date. Vesting occurs over four years with 25% vesting on the first anniversary of the employees' start dates, and the remaining vesting monthly thereafter, contingent on continued employment.

Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x) mKRAS-specific T cell response in all enrolled patients.

Key findings included CD8+ and CD4+ responses in 66.7% of patients at the 4.9 mg dose, and tumor biomarker reductions in 71% of evaluable patients. Antigen-spreading, targeting non-immunizing tumor neoantigens, was observed in all patients at the 4.9 mg dose. The study supports further development, with the recommended Phase 2 dose being 10.0 mg AMP-CpG-7909 with 4.9 mg AMP-Peptides 7P.

Elicio Therapeutics (Nasdaq: ELTX) reported its Q1 2024 financial results and provided corporate updates on its lead cancer vaccine programs, ELI-002 2P and ELI-002 7P.

Q1 financial highlights include a net loss of $11.8 million, increased R&D expenses of $7.6 million, and G&A expenses of $2.7 million. Cash reserves stood at $11.9 million as of March 31, 2024.

ELI-002 2P data was published in Nature Medicine, showing promising immunogenicity and safety. ELI-002 7P is in Phase 2 trials, with preliminary Phase 1 data to be presented at ASCO in June 2024.

Upcoming milestones include completing Phase 2 enrollment for ELI-002 7P by Q4 2024 and providing updated data for ELI-002 2P in Q4 2024.

Elicio Therapeutics, a clinical-stage biotechnology company, will present new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study of ELI-002 7P at the 2024 ASCO Annual Meeting. The study focuses on patients with mKRAS-driven solid tumors and aims to stimulate an immune response against the seven KRAS mutations that drive 25% of all solid tumors.

Elicio Therapeutics, Inc. announces pipeline updates for investigational cancer vaccines at AACR Annual Meeting. ELI-002 shows promising results in mKRAS-driven cancers, inducing durable and potent T cell responses. Preclinical data on ELI-007 and ELI-008 also demonstrate strong immune responses targeting BRAF and p53 mutations.

Elicio Therapeutics, Inc. reported financial results for 2023, highlighting progress in clinical trials and business development. Key points include poster presentations, ongoing Phase 2 trials, successful private placement, and financial data. The company's R&D expenses increased due to clinical trial initiation, while G&A expenses rose from operating as a public entity. Net loss decreased per share, primarily due to a reverse merger. Cash and cash equivalents grew by the end of 2023.

Elicio Therapeutics, a biotechnology company, has entered into a subscription agreement to sell pre-funded warrants to purchase shares of its common stock in a private placement to GKCC, The gross proceeds are expected to be $6.0 million, with the net proceeds intended for the company's development pipeline and general corporate purposes.